JPH0216732B2 - - Google Patents

Info

Publication number: JPH0216732B2
Authority: JP; Japan
Prior art keywords: nana; cmp; acid; pharmaceutical composition; composition according
Prior art date: 1983-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP3634184A

Other languages

English (en)

Japanese (ja)

Other versions

JPS606618A (ja

Inventor

Mitsukori Pietoro

Dekorute Enio

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CHII ERE CHII CO DEI RISERUKA CHIMIKA SpA

Original Assignee

CHII ERE CHII CO DEI RISERUKA CHIMIKA SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-03-01

Filing date

1984-02-29

Publication date

1990-04-18

1984-02-29 Application filed by CHII ERE CHII CO DEI RISERUKA CHIMIKA SpA filed Critical CHII ERE CHII CO DEI RISERUKA CHIMIKA SpA

1985-01-14 Publication of JPS606618A publication Critical patent/JPS606618A/ja

1990-04-18 Publication of JPH0216732B2 publication Critical patent/JPH0216732B2/ja

Status Granted legal-status Critical Current

Links

239000002253 acid Substances 0.000 claims description 15
IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims description 13
IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
210000003169 central nervous system Anatomy 0.000 claims description 8
210000001428 peripheral nervous system Anatomy 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
230000001575 pathological effect Effects 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
235000019800 disodium phosphate Nutrition 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
239000001488 sodium phosphate Substances 0.000 claims description 3
239000008215 water for injection Substances 0.000 claims description 3
239000013543 active substance Substances 0.000 claims 2
201000010099 disease Diseases 0.000 claims 1
239000002502 liposome Substances 0.000 claims 1
229910000160 potassium phosphate Inorganic materials 0.000 claims 1
235000011009 potassium phosphates Nutrition 0.000 claims 1
230000001698 pyrogenic effect Effects 0.000 claims 1
230000000638 stimulation Effects 0.000 claims 1
TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 31
150000001875 compounds Chemical class 0.000 description 21
238000000034 method Methods 0.000 description 19
108090000790 Enzymes Proteins 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 16
210000004027 cell Anatomy 0.000 description 16
150000002270 gangliosides Chemical class 0.000 description 14
239000003381 stabilizer Substances 0.000 description 14
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 13
YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 11
241000700159 Rattus Species 0.000 description 11
PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
239000000872 buffer Substances 0.000 description 9
150000003566 thiocarboxylic acids Chemical class 0.000 description 9
239000012528 membrane Substances 0.000 description 8
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
238000009833 condensation Methods 0.000 description 7
230000005494 condensation Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102000003886 Glycoproteins Human genes 0.000 description 6
108090000288 Glycoproteins Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 6
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 6
229950006874 kainic acid Drugs 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
238000005259 measurement Methods 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
230000006870 function Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
230000007383 nerve stimulation Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
150000004957 nitroimidazoles Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010093096 Immobilized Enzymes Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical class OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
229940060155 neuac Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
SMATWHWTSTWTSA-UHFFFAOYSA-N 1-(5-nitro-1h-imidazol-2-yl)propan-1-ol Chemical compound CCC(O)C1=NC=C([N+]([O-])=O)N1 SMATWHWTSTWTSA-UHFFFAOYSA-N 0.000 description 1
PDQZJILHHPRLIX-UHFFFAOYSA-N 2-(1-ethylsulfanylpropyl)-5-nitro-1H-imidazole Chemical compound CCC(SCC)C=1NC(=CN=1)[N+](=O)[O-] PDQZJILHHPRLIX-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
206010010254 Concussion Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
240000001221 Leucaena esculenta Species 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000009032 Obstetric Paralysis Diseases 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
241000270936 Pelophylax esculentus Species 0.000 description 1
102000003838 Sialyltransferases Human genes 0.000 description 1
108090000141 Sialyltransferases Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
201000011101 acute retrobulbar neuritis Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
238000012769 bulk production Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000003822 cell turnover Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000009514 concussion Effects 0.000 description 1
208000004209 confusion Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000004424 eye movement Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
125000002421 ganglioside group Chemical group 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
235000020905 low-protein-diet Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000035800 maturation Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
230000009207 neuronal maturation Effects 0.000 description 1
230000007511 neuronal proliferation Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
208000021090 palsy Diseases 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
201000002241 progressive bulbar palsy Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
208000022670 retrobulbar neuritis Diseases 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000003901 trigeminal nerve Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
-1 β-ethylthioethyl Chemical group 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)

JP3634184A 1983-03-01 1984-02-29 ５−アセトアミド−３，５−ジデオキシ−ｄ−グリセロ−ｄ−ガラクトノヌロサミン酸のシチジンモノホスフエ−ト含有医薬組成物 Granted JPS606618A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IT83341/83A IT1175061B (it)	1983-03-01	1983-03-01	Applicazione terapeutica del citidin monofosfato dell'acido 5-acetamido-3,5-dideossi-d-glicero-d-galattononulo saminico
IT83341/A/83		1983-03-01
IT83371/A/83		1983-04-20

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1215137A Division JPH0276894A (ja)	1983-03-01	1989-08-23	５―アセトアミド―３，５―ジデオキシ―ｄ―グリセロ―ｄ―ガラクトノヌロサミン酸のシチジンモノホスフェートの製造方法

Publications (2)

Publication Number	Publication Date
JPS606618A JPS606618A (ja)	1985-01-14
JPH0216732B2 true JPH0216732B2 (fr)	1990-04-18

Family

ID=11320404

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP3634184A Granted JPS606618A (ja)	1983-03-01	1984-02-29	５−アセトアミド−３，５−ジデオキシ−ｄ−グリセロ−ｄ−ガラクトノヌロサミン酸のシチジンモノホスフエ−ト含有医薬組成物

Country Status (2)

Country	Link
JP (1)	JPS606618A (fr)
IT (1)	IT1175061B (fr)

1983
- 1983-03-01 IT IT83341/83A patent/IT1175061B/it active
1984
- 1984-02-29 JP JP3634184A patent/JPS606618A/ja active Granted

Also Published As

Publication number	Publication date
IT1175061B (it)	1987-07-01
IT8383341A0 (it)	1983-03-01
JPS606618A (ja)	1985-01-14

Publication	Publication Date	Title
EP0120328B1 (fr)	1988-10-19	Composition pharmaceutique contenent la cytidine monophosphate de l'acide 5-acétamido-3,5-didéoxy-D-glycéro-D-galactononulosamilique
US4329302A (en)	1982-05-11	Synthetic phosphoglycerides possessing platelet activating properties
Schauer	1973	Chemistry and biology of the acylneuraminic acids
Maley et al.	1956	The synthesis of α-D-Glucosamine-1-phosphate and N-Acetyl-α-D-glucosamine-1-phosphate. Enzymatic formation of uridine Diphosphoglucosamine1
MXPA04001831A (es)	2004-07-08	Nuevos derivados sinteticos de gangliosidos y composiciones de los mismos.
HU199860B (en)	1990-03-28	Process for producing ganglioside derivatives and pharmaceutical compositions comprising such active ingredient
JPS60501259A (ja)	1985-08-08	免疫刺激活性をもつ単糖類化合物
Bolhuis et al.	1987	Ganglioside storage, hexosarninidase lability, and urinary oligosaccharides in adult Sandhoff's disease
DE69713514T2 (de)	2003-01-09	Festphasenträgeroberfläche die toxin-bindende oligosaccharide enthalten
WO2013004086A1 (fr)	2013-01-10	Mangiférine fructosylée et son procédé de préparation et son utilisation
GB2179945A (en)	1987-03-18	New saccharides, their preparation and pharmacetical compositions containing them
Sufrin et al.	1980	Halogenated L-fucose and D-galactose analogs: synthesis and metabolic effects
JPH0216732B2 (fr)	1990-04-18
RU2177788C2 (ru)	2002-01-10	Средство для профилактики и лечения инфекционных заболеваний и коррекции патологических состояний живого организма
JPS61176598A (ja)	1986-08-08	シチジン−ジホスフエ−ト−コリンのアシル化誘導体、その製造方法及びその治療的使用
AU754370B2 (en)	2002-11-14	Natural antitumor or antiviral substances and use of the same
US5811539A (en)	1998-09-22	Process for isolating and purifying nucleotide-activated sugars from biological sources
CA1243971A (fr)	1988-11-01	Methode de production d'un cytidine monophosphate de l'acide 5-acetamino-3,5-didesoxy-d-glycero-d- galactononulosaminique
Ponpipom et al.	1987	Inhibition of delayed hypersensitivity reactions by cinnamyl 1-thioglycosides
US7094557B2 (en)	2006-08-22	2-Methyl-3-butenyl-1-pyrophosphoric acid salt and agent for treating lymphocytes
DE3626915A1 (de)	1988-02-11	Verfahren zur enzymatischen synthese eines n-acetylneuraminsaeure-haltigen trisaccharids
Basu	1966	Studies on the biosynthesis of gangliosides
JP3547163B2 (ja)	2004-07-28	無血清培地を用いた物質生産方法
US4504474A (en)	1985-03-12	Synthetic phosphoglycerides possessing platelet activating properties
JPH02111785A (ja)	1990-04-24	スフインゴ糖脂質